Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 57pembrolizumab 54Cetuximab 43Radiotherapy 35Docetaxel 21Radiotherapy, Intensity-Modulated 20Paclitaxel 19Nivolumab 18Fluorouracil 18Carboplatin 17Radiation 14Radiosurgery 9Magnetic Resonance Spectroscopy 8Gemcitabine 8Everolimus 8Biopsy 8Surgical Procedures, Operative 7Oxaliplatin 7Cyclophosphamide 7durvalumab 6avelumab 6Erlotinib Hydrochloride 6Capecitabine 6spartalizumab 5epacadostat 5Surveys and Questionnaires 5Platinum 5Immunoglobulin G 5Gefitinib 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × talactoferrin alfa × Head & Neck × Clear all
NCT01528137 2016-08-02

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Stanford University

Phase 1 Terminated
4 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡